Xiangkun Xu1, Zijian Deng1, Hamid Dehghani2, Iulian Iordachita3, Michael Lim4, John W Wong5, Ken Kang-Hsin Wang6. 1. Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University, Baltimore, Maryland; Biomedical Imaging and Radiation Technology Laboratory, Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, Texas. 2. School of Computer Science, University of Birmingham, Birmingham, West Midlands, United Kingdom. 3. Laboratory for Computational Sensing and Robotics, Johns Hopkins University, Baltimore, Maryland. 4. Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University, Baltimore, Maryland; Department of Neurosurgery, Stanford University, Stanford, California. 5. Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University, Baltimore, Maryland. 6. Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University, Baltimore, Maryland; Biomedical Imaging and Radiation Technology Laboratory, Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, Texas. Electronic address: kang-hsin.wang@utsouthwestern.edu.
Abstract
PURPOSE: Widely used cone beam computed tomography (CBCT)-guided irradiators in preclinical radiation research are limited to localize soft tissue target because of low imaging contrast. Knowledge of target volume is a fundamental need for radiation therapy (RT). Without such information to guide radiation, normal tissue can be overirradiated, introducing experimental uncertainties. This led us to develop high-contrast quantitative bioluminescence tomography (QBLT) for guidance. The use of a 3-dimensional bioluminescence signal, related to cell viability, for preclinical radiation research is one step toward biology-guided RT. METHODS AND MATERIALS: Our QBLT system enables multiprojection and multispectral bioluminescence imaging to maximize input data for the tomographic reconstruction. Accurate quantification of spectrum and dynamic change of in vivo signal were also accounted for the QBLT. A spectral-derivative method was implemented to eliminate the modeling of the light propagation from animal surface to detector. We demonstrated the QBLT capability of guiding conformal RT using a bioluminescent glioblastoma (GBM) model in vivo. A threshold was determined to delineate QBLT reconstructed gross target volume (GTVQBLT), which provides the best overlap between the GTVQBLT and CBCT contrast labeled GBM (GTV), used as the ground truth for GBM volume. To account for the uncertainty of GTVQBLT in target positioning and volume delineation, a margin was determined and added to the GTVQBLT to form a QBLT planning target volume (PTVQBLT) for guidance. RESULTS: The QBLT can reconstruct in vivo GBM with localization accuracy within 1 mm. A 0.5-mm margin was determined and added to GTVQBLT to form PTVQBLT, largely improving tumor coverage from 75.0% (0 mm margin) to 97.9% in average, while minimizing normal tissue toxicity. With the goal of prescribed dose 5 Gy covering 95% of PTVQBLT, QBLT-guided 7-field conformal RT can effectively irradiate 99.4 ± 1.0% of GTV. CONCLUSIONS: The QBLT provides a unique opportunity for investigators to use biologic information for target delineation, guiding conformal irradiation, and reducing normal tissue involvement, which is expected to increase reproducibility of scientific discovery.
PURPOSE: Widely used cone beam computed tomography (CBCT)-guided irradiators in preclinical radiation research are limited to localize soft tissue target because of low imaging contrast. Knowledge of target volume is a fundamental need for radiation therapy (RT). Without such information to guide radiation, normal tissue can be overirradiated, introducing experimental uncertainties. This led us to develop high-contrast quantitative bioluminescence tomography (QBLT) for guidance. The use of a 3-dimensional bioluminescence signal, related to cell viability, for preclinical radiation research is one step toward biology-guided RT. METHODS AND MATERIALS: Our QBLT system enables multiprojection and multispectral bioluminescence imaging to maximize input data for the tomographic reconstruction. Accurate quantification of spectrum and dynamic change of in vivo signal were also accounted for the QBLT. A spectral-derivative method was implemented to eliminate the modeling of the light propagation from animal surface to detector. We demonstrated the QBLT capability of guiding conformal RT using a bioluminescent glioblastoma (GBM) model in vivo. A threshold was determined to delineate QBLT reconstructed gross target volume (GTVQBLT), which provides the best overlap between the GTVQBLT and CBCT contrast labeled GBM (GTV), used as the ground truth for GBM volume. To account for the uncertainty of GTVQBLT in target positioning and volume delineation, a margin was determined and added to the GTVQBLT to form a QBLT planning target volume (PTVQBLT) for guidance. RESULTS: The QBLT can reconstruct in vivo GBM with localization accuracy within 1 mm. A 0.5-mm margin was determined and added to GTVQBLT to form PTVQBLT, largely improving tumor coverage from 75.0% (0 mm margin) to 97.9% in average, while minimizing normal tissue toxicity. With the goal of prescribed dose 5 Gy covering 95% of PTVQBLT, QBLT-guided 7-field conformal RT can effectively irradiate 99.4 ± 1.0% of GTV. CONCLUSIONS: The QBLT provides a unique opportunity for investigators to use biologic information for target delineation, guiding conformal irradiation, and reducing normal tissue involvement, which is expected to increase reproducibility of scientific discovery.
Several groups have initiated efforts to develop small-animal irradiators
that mimic clinical radiation therapy (RT).[1-6] The major
modality used to guide irradiation is cone beam computed tomography
(CBCT).[7-9] However, CBCT is less adept at localizing
soft tissue targets growing in a low image contrast environment, further limiting RT
studies using important (eg, orthotopic and spontaneous) models. Bioluminescence
imaging (BLI) provides strong image contrast; thus, it is an attractive solution for
soft tissue targeting, which has been widely used in tracking malignancy and
assessing its activity. BLI is commonly acquired at a noncontact imaging
geometry,[10-12] based on measurement of emitted
surface light from an internal source. However, because optical transport from an
internal source is susceptible to irregular animal torso and tissue optical
properties, the 2-dimensional BLI is far from being applied to quantify spatial
source distributions and to guide focal irradiation.[13,14]Recognition of these limitations led us to develop 3-dimensional (3D)
bioluminescence tomography (BLT) as the image guidance system for small animal
irradiator. BLT allows the reconstruction of internal bioluminescent source based on
surface BLI.[15-18] Our first BLT was designed to localize the
center of mass (CoM) of an optical target for irradiation.[13,19]
Spherical volume approximation and CoM proposed in our previous work[19] are a workaround when one does not
have actual target volume information for radiation guidance. Knowledge of target
volume is a fundamental need for RT. Without such information to guide radiation,
large portions of normal tissue can be irradiated unnecessarily, leading to
undesired experimental uncertainties. It is imperative that we advance BLT guidance
beyond CoM, to a new and precise level of target volume delineation. The recent work
conducted by Shi et al[20] is
encouraging. They showed the feasibility of applying BLT reconstructed volume to
guide irradiation for 4T1 breast carcinoma grown in mouse mammary fat pad and
observed the BLT volume decrease after irradiation. However, there is still a large
gap between laboratorial development and practical adoption by researchers for their
day-to-day biology experiment. To bridge this gap and to translate BLT-guided
irradiation for practical use by investigators, we present a comprehensive study of
achieving quantitative BLT (QBLT) that enables image-guided conformal irradiation
based on 3D bioluminescence distribution in vivo. In this work, different from our
and other groups’ previous work,[13,19-22] we made great effort not only optimizing
hardware, algorithm, and calibration methods, but also quantifying biologic
variation and providing the approach of designing radiation margin for BLT-guided
RT.In BLT, a model of light propagation through tissue to the skin surface is
used, in conjunction with an optimization algorithm, to reconstruct the underlying
source distribution, which minimizes the difference between calculated and measured
surface BL signal. For our workflow, mice were subject to BLI, and later CBCT
imaging in our small animal radiation research platform (SARRP), followed by BLI
mapped to the animal CBCT image and BLT reconstruction to retrieve target
distribution. To apply QBLT as an image-guided system for conformal irradiation in
vivo, we have optimized the following aspects. First, a multiprojection and
multispectral imaging acquisition was developed to maximize input data information
for tomographic reconstruction. Second, the multispectral BLT heavily relies on the
accurate quantification of the emission spectrum of bioluminescent cells and dynamic
change of in vivo signal. The investigation and corresponding methodology of
quantifying the spectrum and in vivo signal are presented. Third, noncontact imaging
geometry is commonly adopted in optical tomography, but the challenge of accurately
accounting light propagation from tissue surface to optical detector remains. A
novel spectral-derivative algorithm, eliminating the free space light propagation
error and facilitating target delineation, was proposed recently[18] and first applied to animal study. Fourth,
to ensure radiation coverage and to account for QBLT uncertainties in target
localization, we have systematically devised target margin in line with clinic
practice to enable conformal radiation guidance.An orthotopic bioluminescent glioblastoma (GBM) model was chosen to
demonstrate the QBLT-guided RT, because its low imaging contrast represents a
challenging case for CBCT-guided system. We expect that the QBLT-guided small animal
irradiators will provide investigators unprecedented capabilities to localize soft
tissue target, define target volume for conformal irradiation, and facilitate study
reproducibility.
Methods and Materials
System configuration
Our QBLT system was designed as an offline system to maximize the
experiment throughput of both SARRP and optical platform, especially when the
optical system is only needed for longitudinal study, and radiation-guidance and
3D image are not involved. The QBLT system consists of an optical assembly, a
mobile cart, and a transportable mouse bed (Fig.
1a). The assembly is driven by a motorized linear stage to dock onto
a mouse bed for imaging. The assembly includes a charge-coupled device (CCD)
camera (iKon-L936; Andor Technology, Belfast, United Kingdom) mounted with a
50-mm f/1.2 lens (Nikkor; Nikon, Melville, NY), a filter wheel (Edmund Optics,
Barrington, NJ), a 3-mirror system (98% reflective, protected silver coating)
and a light-tight enclosure (Fig. 1b). The
filter wheel with optical filters is used for multispectral image acquisition to
improve BLT reconstruction accuracy.[17,23,24] Four 20-nm FWHM band-pass filters
(Chroma Technology, Bellows Falls, VT) at 590, 610, 630, and 650 nm were used.
The optical signal emitted from an imaged object was directed to the CCD by the
3-mirror system. Each mirror is oriented 45 degrees relative to optical path
(red dashed line, Fig. 1b). The 3-mirror
system can rotate 180 degrees (from −90 to 90 degrees) around imaged
object for multiprojection imaging. The image taken at top of the mouse bed is
labeled as 0-degree projection imaging. In preparation of imaging session, the
imaging chamber was first warmed up with a heat gun (TR89200, 1500W; TR
Industrial, Pomona, CA) (Fig. 1a), and the
temperature was maintained at 37°C by a resistor loop (Brower Equipment,
Houghton, IA) and 7 fans (Digi-Key102-4362-ND; CUI, Tualatin, OR) built inside
the chamber. The characterization of the optical system is described in the
Appendix E1.
Fig. 1.
(a, b) System configuration for the quantitative bioluminescence
tomography. The 3-mirror system attached to the enclosure can rotate and reflect
light from object to charge-coupled device. (c) Transportable mouse bed with
imaging markers (white plastic balls); the nose cone and gas tube are used to
deliver anesthetic gas. (d) Small animal radiation research platform
configuration for cone beam computed tomography acquisition. CCD =
charge-coupled device.
After optical imaging, the mouse bed (Fig.
1c) with animal is transferred from the optical system to SARRP
(Xstrahl, Suwanee, GA) for CBCT imaging and irradiation. On the bed, there are 8
imaging markers (PTFE Balls, 2.4 mm diameter; McMaster-Carr, Santa Fe Springs,
CA) used for data mapping purpose to register surface BLIs with CBCT image (see
Appendix E2. for
data mapping detail). The SARRP consists of an x-ray source mounted on a
360-degree rotational gantry, an amorphous silicon flat panel detector, and a
4-dimensional (3-axis translation and 360° rotation) couch. CBCT imaging
is acquired by rotating the animal between the x-ray source and detector panel
(Fig. 1d). Studied animal was
anesthetized and immobilized during the imaging sessions and transport. It was
operated within 2 m to the SARRP to minimize the effects of transport on the
animal position.[25]
System-specific source spectrum
Because of the multispectral BLT approach, it is important to quantify
the system spectral response and the emission spectrum of bioluminescent cells.
For simplicity, we used the QBLT system for this measurement, which includes
both the system and cell spectral response, and called the resulted spectrum as
system-specific source spectrum. Therefore, the wavelength-dependent BLIs can be
normalized to the measured spectrum weighting, used as the input data for
optical reconstruction. We measured the system-specific spectral weights of
GL261-Luc2 cells at 590, 610, 630, and 650 nm in Petri
dishes with cells >80% confluency with concentration of 0.75 mg of
D-luciferin (PerkinElmer, Waltham, MA) per 1 mL of phosphate buffer solution.
Open-field images without filters were taken before and after each spectral BLI
to quantify the in vitro signal variation over time and to eliminate the
variation of the in vitro signal as a function of luciferin incubation time. The
measured spectrum of the GL261-Luc2 at 590, 610, 630, and 650
nm at 37°C is 1, 0.916 ± 0.014, 0.674 ± 0.019, and 0.389
± 0.012 (n = 20), respectively. To assess the spectrum change as function
of ambient temperature, we compared 2 conditions 24°C and 37°C
representing our BLT system setting without and with the thermosystem turned on,
respectively.
Quantify time-resolved in vivo bioluminescence signal
Because in vivo bioluminescence signal can vary over time, and because
the change can be animal specific, it is important to quantify the time-resolved
in vivo signal for having accurate input data for reconstruction. To build the
time-resolved curve for each projection during BLI acquisition, open-field
images taken before and after each spectral image along with the time points
when the images were taken were used to record the signal variation overtime. A
region of interest (ROI) was chosen in the open field image. Because the ROIs in
different projections were not from the same physical location of animal
surface, the time-resolved curves between 2 adjacent projections were linked by
extrapolating the light intensity from the time-resolved curve of the first
projection to the time point when the first open-field image at the second
projection was measured. The light intensity recorded from the second projection
at this time point was scaled according to the extrapolated light intensity from
the first projection. We can therefore combine the time-resolved curves among
different projections, quantify the dynamic change of in vivo signal during
imaging course, and correct the intensity of each spectral BLI taken at certain
time point.
Spectral-derivative method for QBLT reconstruction
For the spectral-derivative method, we used the ratio of the BLIs at
adjacent wavelengths as input data for optical reconstruction, as
bioluminescence at similar wavelengths encountering a near-identical system
response. The mathematical framework can be found in the Appendix E3 or reference.[18] Briefly, the goal of BLT is to
solve the BL source distribution or power density, S in Eq. (1) derived from diffusion
approximation,[26]
where G is a sensitivity
matrix for a given wavelength λ related to changes in
the measured boundary/surface BLI signal b,
G can be constructed from prior
knowledge of the optical property of subject, and n is a
measurement point specific angular dependent offset to account for the
difference between actual surface fluence rate
φ and
b, and n is assumed
to be spectrally invariant, and w is the
system-specific spectrum of the light source. By applying logarithm to Eq. (1), and considering the ratio
of the data between 2 neighboring wavelengths
λ and
λ, we can write the spectral-derivative form of Eq. (1) asWe solved the source distribution S iteratively by
applying compressive sensing conjugate gradient optimization algorithm[27] under finite element framework
provided by NIRFAST software.[28]
In vivo QBLT validation
To establish the GBM model, GL261-Luc2 cells were
implanted into the left striatum of C57BL/6J mouse (6-8 weeks old, female; The
Jackson Laboratory, Bar Harbor, ME) at 3 mm away from burr hole/surgical
opening. The GBM-bearing mice, 2 weeks after the implantation, were subject to
multispectral and multiprojection BL imaging 10 minutes after D-Luciferin
injection. Because the in vivo signal at 590 nm was weak compared with that of
other spectral image, which affects the stability of the spectral-derivative
method, we chose the images at 610, 630, and 650 nm for QBLT reconstruction for
the results presented here. The BLIs were then mapped onto the mesh surface of
the imaged mouse generated from the CBCT image. The mapped surface data larger
than 10% of the maximum value among all the surface points were used as input
data for QBLT reconstruction. The detail of animal preparation and imaging
acquisition and the parameters used in QBLT reconstruction can be found in Appendix E4 and E5, respectively.Contrast CBCT was used to define the gross target volume (GTV) of GBM
bearing mice as the ground truth to validate the accuracy of QBLT target
localization. After QBLT imaging session, the mouse was moved to our
high-resolution CBCT system[29]
for the contrast imaging. The mouse was imaged 1 minute after the contrast
injection at dose of 2 gI/kg (Iodixanol, retro-orbital injection 160
μL at 320 mgI/mL; Visipaque, GE Health Care,
Chicago, IL). The mouse head region in SARRP CBCT and contrast CBCT image were
registered with 3D Slicer (version 4.10.2; https://www.slicer.org/).[30] The GTV was first segmented with 3D Slicer (see Appendix E6) and compared
with the GTV reconstructed by QBLT (GTVQBLT). We determined the
threshold, based on the maximum value of QBLT reconstructed power density
distribution [S, Eq.
(1)], best delineating the GTVQBLT, by analyzing the Dice
coefficient between GTVQBLT and GTV, as 2(GTVQBLT ∩
GTV)/(GTVQBLT + GTV).
In vivo QBLT-guided conformal irradiation
A margin accounting for the uncertainty of QBLT target localization (eg,
positioning and volume determination) was added to GTVQBLT to form a
QBLT planning target volume (PTVQBLT) for radiation guidance. We
generated a 7-field conformal radiation plan using an SARRP treatment planning
system with the goal of 5 Gy as the prescribed dose to cover 95% of the
PTVQBLT and 100% of the GTVQBLT. To confirm the
QBLT-guided GBM irradiation qualitatively, we perform the pathologic analysis
with immunohistochemical staining (see Appendix E7) to visualize cell
nuclei and DNA double-strand breaks using DAPI and
γ-H2AX, respectively.
Data distribution and statistical analysis
Nonparametric box plots (MATLAB R2019b; MathWorks, Natick, MA) were used
to display distributions of the Dice coefficients as a function of threshold
values, tumor and normal tissue coverage as function of PTVQBLT
margin size, and dosimetric parameters for single field and QBLT-guided plan
comparison. The area between the bottom (25%) and top (75%) of the box edge
indicates the degree of data spread. The “black band” within the
box represents the 50th percentile, or median number. An outlier is defined as
the data falling outside the range of q3 +
w × (q3 −
q1) to q1 −
w × (q3 −
q1), where w is the maximum
whisker length, and q1 and
q3 are the 25th and 75th percentiles of the
sample data, respectively. The MATLAB default value of w = 1.5
was used; it renders, at a given normal distribution, the data falling beyond
the whisker length corresponds to 0.7% coverage of the data, outside 2.7
standard deviation.Statistical significance of differences in averages was determined using
a 2-tailed paired Student t test (Microsoft Excel 2016;
Microsoft, Redmond, WA); P < .05 was considered
significant.
Results
The effect of ambient temperature and the quantification of interanimal
signal variation
Figure 2a shows that in vitro BL
intensity of the GL261-Luc2 cells can increase significantly by
2-fold as the ambient temperature increases from 24°C to 37°C.
Beyond maintaining physiologic function, keeping animal at the normal body
temperature of 37°C during BL imaging session is also favorable to
shorten the image acquisition time, and therefore increase throughput. Figure 2b further illustrates that the
system-specific spectrum of the GL261-Luc2 cells can be
red-shifted, when ambient temperature is increased.
Fig. 2.
Temperature effect on bioluminescence signal in vitro and quantification
of interanimal signal variation. (a) In vitro light intensity of
GL261-Luc2 cells versus ambient temperature (n = 5). (b)
System-specific spectrum of GL261-Luc2 for 24°C (n = 6)
and 37°C (n = 20). Error bars represent standard deviation. (c) Dynamic
change of in vivo bioluminescence signal for 3 glioblastoma-bearing mice,
normalized to maximum intensity. (d) Mouse 3 from (c) is used to illustrate the
formation of the overall time-resolved curve combined from 3 projections.
Figure 2c shows the time-resolved
in vivo BL signal is animal-specific. For each imaged animal, as one can take
spectral BLIs at different time points, the animal-specific signal variation
could affect the accuracy of the input spectral BL data. We use mouse 3 from
Figure 2c as an example; with the
method described previously, we can build the animal-specific time-resolved
bioluminescence curve over the entire multiprojection imaging course (Fig. 2d). With this curve, we can eliminate
the effect of interanimal and physiologic variation on each spectral BLI taken
at a certain time point.
In vivo QBLT
To demonstrate the QBLT capability in retrieving target in vivo,
GBM-bearing mice were used for BL imaging and reconstruction. Figure 3a shows the BLIs taken at −90, 0, and
90 degrees projection, and then mapped to the mesh surface generated from the
mouse CBCT image (Fig. 3b). The
corresponding GTVQBLT is qualitatively matched to the GTV (Fig. 3c), if a threshold 0.5 of maximum
reconstructed BL power density was applied. We justify the 0.5 threshold as the
optimal value for QBLT in target delineation using Dice coefficient (Fig. 3d), with the most overlapped volume
between the GTVQBLT and GTV. Furthermore, although there is no
significant difference of the Dice coefficient between the threshold 0.5 and 0.6
groups, the variation of the data spread is smaller, and the median value of the
Dice coefficient is larger for the 0.5 group than that for the 0.6 group. These
reasons support our choice of picking the 0.5 threshold value to delineate the
GTVQBLT. As the threshold was continuously increased,
GTVQBLT became smaller, and deviated from the GTV, introducing
larger data spread as shown in the cases of threshold 0.7-0.8. Moreover, the
deviation of CoMs between GTVQBLT and GTV is 0.62 ± 0.16 mm (n
= 10). The individual 10 mice result of the GTVQBLT coverage can also
be found in Figure
E1.
Fig. 3.
In vivo quantitative bioluminescence tomography (QBLT) reconstruction
and threshold determination; (a) Bioluminescence imaging (630 nm; heat map) of a
2-week-old glioblastoma-bearing mouse taken at 3 projections. (b) The 3
projection bioluminescence images in (a) mapped onto the surface of the mouse
head mesh. The mapped surface data larger than 10% of the maximum value among
all the 3 projections is displayed in (a) and (b). (c) The overlap of
GTVQBLT (heat map, threshold at 0.5) and GTV (blue contour,
contrast-labeled glioblastoma). (d) Dice coefficient between gross tumor volume
(GTV) and GTVQBLT versus threshold of maximum QBLT reconstructed
value (n = 10); each red circle represents one mouse data point. The asterisk
indicates no significant difference (P > .05) of Dice
coefficient between the threshold of 0.5 and 0.6 groups.
Margin design for PTVQBLT
Although the GTVQBLT qualitatively matches the GTV (Fig. 3c), there is still deviation between
the 2 quantities in terms of volume and positioning. To account for these
deviations and to ensure irradiation coverage of the tumor volume, we added a
uniform margin to GTVQBLT and formed the PTVQBLT for
radiation guidance. We investigated optimal margin size by evaluating the GBM
volume coverage with conformal index of (PTVQBLT ∩ GTV)/GTV
and normal tissue coverage with (PTVQBLT – PTVQBLT
∩ GTV)/Vhead, where Vhead is the volume of mouse
head (Fig. 4a). Without margin (0 mm
expansion), large variation of tumor coverage is expected, average 75.0% varying
from 63.6% to 84.7% within 25% to 75% data range and median number at 76.4%. We
observed with merely a 0.5-mm margin expansion, the GTV can be covered by the
PTVQBLT at average 97.9% with much smaller variation
(97.6%–99.9%) within 25% to 75% data range and median number at 99.2%,
compared with the case of 0 mm margin, while the normal tissue inclusion is only
at average 1.2%. As we further increased the margin, the benefit of tumor
coverage is not statistically significant, but more normal tissue toxicity is
introduced. We therefore chose 0.5 mm margin for the studies described later. A
representative case is shown in Figure
4b–d to illustrate the
PTV margin expanded from reconstructed GTVQBLT. Other individual mice
result of margin application can also be found in Figure E1.
Fig. 4.
Margin design. (a) Tumor coverage (red circle, left axis) and normal
tissue coverage (blue cross, right axis) versus margin expansion for 2-week-old
glioblastoma. Asterisk indicates no significant difference (P
> .05; n = 10) of the tumor coverage between the margin groups. Each
circle and cross represent one mouse data point. (b-d) Representative case of a
0.5-mm margin added to a quantitative bioluminescence tomography reconstructed
gross target volume (GTVQBLT) (heat map) to form a PTVQBLT
(cyan). The blue contour is GTV (contrast-labeled glioblastoma). PTV = planning
target volume.
Figure 5a1–a3 shows a representative case of a 7-field
noncoplanar beam arrangement to cover the PTVQBLT (Fig. 4b–d). A 5 × 5-mm2 beam collimator was used, and the CoM
of GTVQBLT was set as the beam isocenter (pink points). The
corresponding dose distributions are shown in Figure 5b1–b3, where 5
Gy was prescribed to cover 95% of the PTVQBLT. Although we were
limited by available collimator size, the QBLT-guided 7-field plan can still
effectively cover the PTVQBLT and GTV. For comparison, we generated
the dosimetric plan of single beam irradiation (Fig. 5c1–c3), commonly
used in radiobiology studies.[31-34]
Because of the lack of soft tissue contrast and volumetric information for
conventional CBCT-guided system, the common approach for GBM irradiation is
setting radiation isocenter at cell implantation location and directing single
beam through a surgical burr hole.[31,34] Because no
tumor volume information is available, one can only guide the irradiation by the
surgical opening at the skull surface indicated in the CBCT. The
contrast-labeled GBM (GTV, blue contour in Fig.
5c1–c3) was only used to
compare the dosimetric coverage of the GBM volume between the single beam and
QBLT-guided 7-beam plan. For a day-to-day biology experiment, the contrast image
is not ideal for image guidance using SARRP, which is limited by fast contrast
clearance and SARRP CBCT performance. For the single-beam scenario presented in
this study, 5 Gy was prescribed to the cell implementation site (yellow dots) 3
mm away from the opening. The single-field plan under-dosed the GTV (red line
vs. blue contour) and led to undesired normal tissue irradiation. The
dose-volume histogram (Fig. 5d) shows 100%
of GTV covered by the 5-Gy prescribed dose with the 7-field conformal plan, and
in contrast, only 54% coverage is seen from the single field plan. The
GTVQBLT is also 100% covered by the 7-field plan. It is expected
that the 7-field plan introduced a larger portion of low-dose bath in a normal
tissue region, which is a trade-off for high conformality of target coverage and
reduction of the normal tissue toxicity at high dose. From our mice cohort (n =
10), with QBLT-guided conformal irradiation, we can achieve 100% of the
prescribed dose covering 99.4 ± 1.0% (capped at 100%) of GTV versus 65.5
± 18.5% coverage with the single field irradiation. We further compare
the target volume coverage for the single-field and QBLT-guided 7-field plan
using the metrics of D100, D50 and D2 (Fig. 5e). Taking the D100 as an
example, it is the deposited dose being able to cover 100% of the GTV. These
metrics indicate the dosimetric heterogeneities introduced by a given
irradiation technique. The D100 boxplot shows that none of the
single-field plan can deliver the prescribed dose of 5 Gy covering 100% of GTV,
and 40% of the animals did not even reach D100 at 4 Gy. The large box
size and extensive D100 variation (0.1-4.9 Gy) renders large
experimental uncertainty. In contrast, for QBLT-guided 7-field irradiation,
D100 of GTV only vary from 4.9 to 5.5 Gy within 25% to 75% data
range, with a minimum 4.5 Gy, maximum 6.2 Gy, and median value at 5.2 Gy, which
indicates superior tumor coverage and smaller dose variation. Larger
D50 and D2 are expected in the case of both 7-field
GTV and GTVQBLT, compared with the single-field group, because of the
prescribed dose aimed to cover PTVQBLT, leading to a larger hot
region inside the GTV and GTVQBLT. We further compared the
D100, D50 and D2 between the GTV and
GTVQBLT group, and there is no significant difference between
these metrics. This result suggests that one could use GTVQBLT to
evaluate the dosimetric coverage of GTV.
Fig. 5.
In vivo QBLT-guided conformal irradiation. (a1-a3) Representative case
of a 7-field noncoplanar plan; the GTV is delineated in blue contour. Five
coplanar fields (couch at 0 degree, and gantry at −60, 60, 90, 140, and
180 degrees) are indicated with white arrows, and 2 noncoplanar fields (couch at
−40 and 40 degrees, gantry at −60 degrees) are indicated with the
yellow dashed arrows. The weighting of each irradiation field is 12.5%, except
for the beams at couch 0 degree and gantry 180 degrees with weighting of 25%.
(b1-b3) Dose distributions for the 7-field plan (a1-a3), with 5 Gy as the
prescribed dose to cover the QBLT planning target volume. (c1-c3) Dose
distributions for single-beam delivery, with 5 Gy prescribed to the isocenter
(yellow dot). (d) Dose-volume histogram of the 7-field QBLT-guided (b1-b3) and
single-field (c1-c3) irradiation for PTVQBLT, GTVQBLT,
GTV, and normal tissue. (e) Dose deposited at 100% (D100), 50%
(D50), and 2% (D2) of the target volume for GTV under
the single field irradiation, GTV under the 7-field QBLT-guided irradiation, and
GTVQBLT under the 7-field QBLT-guided irradiation (n = 10). Black
dashed line indicates the prescribed dose of 5 Gy. The asterisk indicates no
significant difference (P > .05; n = 10) of
D100, D50, and D2 between the GTV and
GTVQBLT groups for the 7-field treatment plan.
Abbreviations: GTV = gross tumor volume; NT = normal
tissue; PTV = planning target volume; QBLT = quantitative bioluminescence
tomography.
Because of the limitation of pathologic staining, we used 2 mice to
demonstrate the 3D feature of the QBLT-guided conformal irradiation (Fig. 6). The high-dense DNA region/GBM
location shown in the DAPI images (Fig.
6a1–a2) is overlapped
well with the irradiated area stained by the γ-H2AX
(Fig. 6b1–b2, 6c1–c2). These results
confirm that QBLT can guide SARRP to effectively irradiate the GBM. It is worth
noting that γ-H2AX staining is highly sensitive to
radiation, and it is challenging to determine the exact threshold dose inducing
the DNA double-strand breaks. We did not use γ-H2AX
staining as quantitative measure, but a qualitative method to confirm the GBM
irradiation. In fact, even the dose outside GBM is low, and
γ-H2AX can still reveal one of the radiation beam
passage (Fig. 6b2).
Fig. 6.
Pathologic confirmation of QBLT-guided conformal irradiation. (a1-b1,
a2-b2) 4,6-diamino-2-phenylindole and γ-H2AX staining in
transverse and coronal sections from 2 mice, respectively. (b1-b2) White solid,
double dash, and double line arrows indicate the glioblastoma, normal tissue,
and low-dose normal tissue irradiated area, respectively. (c1 and c2) Composite
images. Abbreviations: DAPI = 4,6-diamino-2-phenylindole; GBM =
glioblastoma; QBLT = quantitative bioluminescence tomography.
Discussion
CBCT-guided irradiation[1,2,4,6] provides guidance
capability, but it is limited to localized soft tissue targets. Although one might
consider contrast imaging for target delineation, because of fast clearance and the
use being limited to well-vascularized tumor models, it is not an ideal modality to
guide irradiation. BLI thus offers an attractive solution; however, the intensity
and distribution of commonly used techniques are nonlinearly dependent on the
spatial location of internal source, tissue optical properties, and animal
shape.[35] Thus, the spatial
distribution of bioluminescent tumor is not accessible for quantitation with BLI. It
is imperative to develop the QBLT to accurately quantify the spatial distribution of
the underlying tumor for radiation guidance. Several recent studies have shown the
potential of applying BLT for radiation guidance.[13,19-22] The
significance of this work is that we devised a comprehensive approach to
systematically tackle the known challenging of optical tomography for in vivo target
delineation, quantify its uncertainties in both biology and tissue optics for
localization, and present the practicality for radiation guidance. Through this
work, we expect to increase the recognition of BLT and its adoption for
biology-guided irradiation.Considering the underdetermined nature of BLT, we chose the multiprojection
and multispectral imaging acquisition to maximize input information for QBLT
reconstruction.[17,23] Accurate target reconstruction
depends on whether we have correct surface images as input. Ambient temperature does
not just affect imaging acquisition time or experiment throughput; it also affects
the accuracy of the multispectral BLT reconstruction, which is closely related to
the BL spectrum (Fig. 2a–b). The in vitro cell spectrum is part of our input
information for the multispectral BLT reconstruction. Therefore, it is necessary to
maintain a consistent ambient temperature (preferably 37°C) equal to the
temperature of a normal mouse body, between the in vitro spectrum measurement and in
vivo bioluminescence imaging acquisition. We also presented that the kinetics of in
vivo luciferin uptake is animal specific (Fig.
2c–d), which can affect the
amplitude of the surface spectral data taken at different time points and
potentially lead to erroneous BLT target localization. Furthermore, in noncontact
imaging geometry, one major challenge is accounting for the light propagation from
the skin to the optical detector. Existing approaches typically use a model of the
imaging system that is usually computationally intensive or of limited
accuracy.[36,37] As the BLIs at adjacent wavelengths
encounter a near-identical system response, the spectral-derivative method[18] eliminates the need for
complicated system modeling. With our comprehensive approaches, we demonstrate that
QBLT is able to define approximated GBM volume in vivo with the localization
accuracy <1 mm.The distribution of the BLT-reconstructed volume depends on the choice of
threshold, which determines the accuracy of radiation guidance. There are various
threshold values used in optical tomography studies.[38-40] The challenge of threshold selection in BLT is finding the
value best representing actual target volume throughout study animals. We derived
the strategy that determines the optimal threshold value 0.5 using the Dice
coefficient (Fig. 3d). Although the optimal
threshold provides encouraging result of delineating the GBM volume (Fig. 3c), the QBLT-reconstructed volume is inevitably
suffered from the resolution limitation and multiple scattering nature of diffuse
optical tomography where actual tumor shape delineation is challenging. We innovated
designing a margin to account for the uncertainties of QBLT in target localization.
Without margin, a large variation of tumor coverage is expected, which translates to
large experimental uncertainties. In contrast, after adding a 0.5-mm margin, the
averaged tumor coverage was largely improved from 75.0% to 97.9%, and the variation
was significantly reduced (Fig. 4a). The
PTVQBLT was designed to account for the localization uncertainties of
the GTVQBLT in target positioning and volume delineation. Regarding the
potential positioning error caused by animal transport, from our study,[25] as long as animals are
anesthetized with effective immobilization during transport and the off-line optical
system is in close proximity (< 5 m) to SARRP, the positioning error can be
maintained within 0.2 mm. Most importantly, when we mapped the 2-dimensional
bioluminescence images to the surface of 3D mesh generated from SARRP CBCT image,
this positioning error, if any, will be propagated to the data mapping and finally
to the BLT reconstruction, which had been accounted in PTVQBLT. The SARRP
irradiation uncertainty and the image registration uncertainty between SARRP CBCT
imaging and our in-house contrast CBCT imaging could be considered further. However,
published results have shown that SARRP can deliver the radiation dose at 0.2-mm
accuracy.[41] The
uncertainty of image registration between SARRP CBCT and our in-house contrast CBCT
for mouse brain is within 0.25 mm at the image pixel limit. By adding these
uncertainties into our 0.5-mm margin using root sum–squared method, the
overall margin would be 0.59 mm, not significantly larger than the 0.5 mm margin.
This finding suggests that the major uncertainty for target localization is
contributed from the BLT reconstructed volume, GTVQBLT. Moreover, our
immunohistochemical staining results have qualitatively validated that
PTVQBLT can guide SARRP to effectively irradiate the GBM (Fig. 6). Thus, the PTVQBLT derived in
our study is a reasonable estimation to provide sufficient GBM coverage for the
QBLT-guided RT. Nevertheless, researchers who are interested in using the
QBLT-guided RT can follow our approach and further optimize the margin size for
target coverage based on their research purposes, and irradiator-specific
localization errors.The margin is critical in that it does not only reduce the variation of
target coverage but also provides a practical radiation planning volume to make
conformal RT possible. It is significant that now we can mimic clinical RT in an
orthotopic model to reduce normal tissue involvement and align in vivo experiments
with clinical practice. From Figures
5b1–b3, versus 5c1–c3, and
5d, the optical-guided conformal
irradiation is far superior than the traditional single field irradiation which can
miss target and may lead to wrong experiment conclusions owing to large variation of
tumor coverage (Fig. 5e). The similar
D100, D50, and D2 between the GTV and
GTVQBLT coverage further validate that with the PTVQBLT
derived by proper threshold and margin selection, we can perform high-contrast,
optical image–guided irradiation. Our current treatment plan is limited by
available collimator size from the commercial SARRP and forward treatment plan
scheme. We designed the 7-field conformal plan (Fig.
5a1–a3) with empirically
selected gantry and couch positions. In a clinical setting, one would use a
multileaf collimator combined with inverse planning to design optimal collimator
opening and beam orientation to provide conformal dose coverage. However,
preclinical radiation research technology is still behind that of clinical RT, and
the advance techniques are underdeveloped.[42-44] With these
technologies, one would expect that the dose conformality (Fig. 5b1–b3,
5e) can be improved.It is worth mentioning that QBLT-guided RT is not limited by the brain tumor
model presented in this work. Our preliminary result of applying QBLT-guided
conformal irradiation for an orthotopic pancreatic tumor model demonstrated 1.2-mm
localization accuracy with 95% PTVQBLT coverage at the prescribed dose
(Appendix E8 and Fig. E3). However, guiding
irradiation for abdominal tumor is not trivial, because it involves organ movement
and strong optical tissue heterogeneities. Further investigation of applying
QBLT-guided irradiation for abdominal tumor is ongoing.This work is significant advance of our previously published BLT-guided CoM
irradiation.[19] Because of
technology constraints, we were able to provide only the CoM location of a
bioluminescent target, and we had to estimate tumor volume by equivalent sphere,
established from a tumor growth curve.[19] The spherical volume is designed to be conservative to not miss
the target. Despite providing good tumor coverage, it inevitably includes large
normal tissue region as discussed previously.[19] With all the developments described here, we could leap
toward the quantitative biology-guided irradiation from the geometric-guided scheme
(CoM point and equivalent sphere). With QBLT, one does not need to know the tumor
growth information to estimate volume, which can be challenging for orthotopic and
spontaneous model. The QBLT-guided irradiation is one step closer to a clinical
scenario that we can tailor radiation to the reconstructed bioluminescence volume
and reduce normal tissue toxicity. Using 2-week-old in vivo GBM as an example, our
data shows the volume of normal tissue involvement within PTVQBLT (36.2
± 9.8 mm3) derived from the QBLT is half of that (77.6 ±
4.7 mm3) from the estimated sphere method.[19]BLI has served as common surrogate to inform tumor activity. One can
potentially use the QBLT-reconstructed volume and its BL power to quantify tumor
viability in response to therapeutic intervention. The analogy can be found in
positron emission tomography–guided irradiation for radiation planning and
tumor response evaluation.[45,46] The QBLT thus complements
CBCT-guided irradiators by providing researchers new capabilities for defining
target volume for conformal RT, and noninvasively quantifying treatment outcome.
Conclusion
We have enabled quantitative BLT-guided irradiation by optimizing the
hardware, algorithm, and calibration method and by addressing the uncertainties
introduced by biology and tissue optics in target localization and volume
delineation. Our QBLT platform will enhance preclinical RT research with the
capabilities of functional targeting beyond anatomic imaging.
Authors: Yidong Yang; Ken Kang-Hsin Wang; Sohrab Eslami; Iulian I Iordachita; Michael S Patterson; John W Wong Journal: Med Phys Date: 2015-04 Impact factor: 4.071
Authors: Edward E Graves; Hu Zhou; Raja Chatterjee; Paul J Keall; Sanjiv Sam Gambhir; Christopher H Contag; Arthur L Boyer Journal: Med Phys Date: 2007-11 Impact factor: 4.071
Authors: James A Guggenheim; Hector R A Basevi; Iain B Styles; Jon Frampton; Hamid Dehghani Journal: J Opt Soc Am A Opt Image Sci Vis Date: 2013-12-01 Impact factor: 2.129
Authors: Jing Zeng; Alfred P See; Jillian Phallen; Christopher M Jackson; Zineb Belcaid; Jacob Ruzevick; Nicholas Durham; Christian Meyer; Timothy J Harris; Emilia Albesiano; Gustavo Pradilla; Eric Ford; John Wong; Hans-Joerg Hammers; Dimitris Mathios; Betty Tyler; Henry Brem; Phuoc T Tran; Drew Pardoll; Charles G Drake; Michael Lim Journal: Int J Radiat Oncol Biol Phys Date: 2013-02-22 Impact factor: 7.038
Authors: Niloufar Zarghami; Donna H Murrell; Michael D Jensen; Frederick A Dick; Ann F Chambers; Paula J Foster; Eugene Wong Journal: Radiat Oncol Date: 2018-06-01 Impact factor: 3.481
Authors: Andrew J Gunderson; Tomoko Yamazaki; Kayla McCarty; Michaela Phillips; Alejandro Alice; Shelly Bambina; Lauren Zebertavage; David Friedman; Benjamin Cottam; Pippa Newell; Michael J Gough; Marka R Crittenden; Pieter Van der Veken; Kristina H Young Journal: PLoS One Date: 2019-02-06 Impact factor: 3.240